These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28551657)

  • 1. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
    Wang W; Zhong W; Chen C; Meng Q; Wei J
    Anticancer Res; 2017 Jun; 37(6):3151-3155. PubMed ID: 28551657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer.
    Wang W; Guan S; Sun S; Jin Y; Lee KH; Chen Y; Wei J
    Tumour Biol; 2014 May; 35(5):4901-5. PubMed ID: 24453033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
    Liang T; Han Z; Zhao H; Zhang X; Wang Y
    Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
    Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
    Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of circulating antibodies to ANXA1 in breast cancer.
    Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
    Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
    Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
    Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
    Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.
    Xu S; Huangfu M; Jia X; Song X; Sun B; Lee KH; Liu L; Sun S
    Int J Clin Oncol; 2015 Oct; 20(5):982-8. PubMed ID: 25681877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?
    Liu L; Liu N; Liu B; Yang Y; Zhang Q; Zhang W; Yu P; Jin Y; Guo J; Guan S; Sun S; Miao L; Wei J
    J Cancer Res Clin Oncol; 2012 Oct; 138(10):1737-42. PubMed ID: 22699933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer.
    Farlow EC; Patel K; Basu S; Lee BS; Kim AW; Coon JS; Faber LP; Bonomi P; Liptay MJ; Borgia JA
    Clin Cancer Res; 2010 Jul; 16(13):3452-62. PubMed ID: 20570928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
    Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
    J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
    Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
    Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
    Liu S; Zhang X; Jiang Q; Liang T
    FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker studies abound for early detection of lung cancer.
    Brower V
    J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer.
    Tantai J; Hu D; Yang Y; Geng J
    Int J Clin Exp Pathol; 2015; 8(7):7887-95. PubMed ID: 26339353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further study of circulating IgG antibodies to CD25-derived peptide antigens in nonsmall cell lung cancer.
    Chen C; Wang W; Meng Q; Wu N; Wei J
    FEBS Open Bio; 2016 Mar; 6(3):211-5. PubMed ID: 27047749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro.
    Fang Y; Guan X; Cai T; Long J; Wang H; Xie X; Zhang Y
    Mol Med Rep; 2016 May; 13(5):3858-66. PubMed ID: 27035116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
    Chen SS; Li K; Wu J; Peng ZY; Wang ZD; Wang JC; Xu CW; Zhu CL; Li BC; Ren H; Tang SC; Sun X
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):223-233. PubMed ID: 32691153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells.
    Tao H; Mimura Y; Aoe K; Kobayashi S; Yamamoto H; Matsuda E; Okabe K; Matsumoto T; Sugi K; Ueoka H
    Lung Cancer; 2012 Jan; 75(1):95-101. PubMed ID: 21719142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rethinking Autoantibody Signature Panels for Cancer Diagnosis.
    Campa MJ; Gottlin EB; Herndon JE; Patz EF
    J Thorac Oncol; 2017 Jun; 12(6):1011-1014. PubMed ID: 28126538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.